Category
PHS Pricing Under Pressure: Managing Duplicate Discounts and Diversion Risks in 2025
Duplicate discounts and diversion are two of the most persistent risks in pharmaceutical pricing, and in 2025, they’re under the microscope. HRSA audits are tougher, state-level carve-in/carve-out rules are more complex, and manufacturers are expected to prove not only that they have controls in place, but that those controls are… Read More